Encompass Health

EHC

Market cap $10.6B

NEW YORK, April 14, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Encompass Health Corporation (“Encompass” or the “Company”) (NYSE: EHC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

The average of price targets set by Wall Street analysts indicates a potential upside of 31.7% in Encompass Health (EHC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

NEW YORK, April 9, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Encompass Health Corporation ("Encompass" or the "Company") (NYSE: EHC).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

BIRMINGHAM, Ala., April 8, 2026 /PRNewswire/ -- Encompass Health Corp. (NYSE: EHC) will hold its annual meeting of stockholders at 11 a.m.

NEW YORK, April 07, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Encompass Health Corporation (“Encompass” or the “Company”) (NYSE: EHC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

BIRMINGHAM, Ala., April 7, 2026 /PRNewswire/ -- Encompass Health Corp. (NYSE: EHC) today announced it will report results for its first quarter ended March 31, 2026, after the market closes on Thursday, April 30, 2026.

Encompass Health (EHC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).